A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
暂无分享,去创建一个
David S Mendelson | Michael K Wong | H. Hurwitz | W. Figg | L. Rosen | C. Theuer | J. Goldman | M. Gordon | S. Spencer | William D Figg | B. Seon | Charles P Theuer | Delia Alvarez | D. Mendelson | Lee S Rosen | Herbert I Hurwitz | Jonathan Goldman | Shawn Spencer | Bonne J Adams | Ben K Seon | Bryan R Leigh | Michael S Gordon | B. Leigh | M. Wong | B. Adams | D. Alvarez
[1] J. Berlin,et al. Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis. , 2012 .
[2] Yin Zhang,et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] A. Berner,et al. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status , 2011, Tumor Biology.
[4] N. Choong,et al. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. , 2011, The New England journal of medicine.
[5] B. Seon,et al. Endoglin-targeted cancer therapy. , 2011, Current drug delivery.
[6] A. Ravaud,et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Seon,et al. Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature , 2009, International journal of cancer.
[9] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[10] G. Camussi,et al. Identification of a tumor‐initiating stem cell population in human renal carcinomas , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] S. Misbah,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[12] L. Ellis,et al. Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy , 2008, Clinical Cancer Research.
[13] Quynh-Thu Le,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[14] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[15] G. Guanti,et al. Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects. , 2006, Current pharmaceutical design.
[16] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[17] W. Greco,et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin , 2006, Cancer Immunology, Immunotherapy.
[18] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Dinney,et al. Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts , 2004, Cancer Research.
[20] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[21] R. Dillman,et al. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. , 2003, Supportive cancer therapy.
[22] D. Fukumura,et al. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] A. Olshen,et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma , 2003, British journal of haematology.
[24] P. Carmeliet. Angiogenesis in health and disease , 2003, Nature Medicine.
[25] Shant Kumar,et al. CD105 is important for angiogenesis: evidence and potential applications , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] Liang‐Kung Chen,et al. Hereditary hemorrhagic telangiectasia. , 2020, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.
[27] T. Sanchez-Elsner,et al. Endoglin Expression Is Regulated by Transcriptional Cooperation between the Hypoxia and Transforming Growth Factor-β Pathways* , 2002, The Journal of Biological Chemistry.
[28] B. Seon,et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.
[29] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[30] B. Brooke,et al. Defective angiogenesis in mice lacking endoglin. , 1999, Science.
[31] A. Cattelan,et al. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. , 1996, British Journal of Cancer.
[32] M. Cohen,et al. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. , 1995, Journal of immunology.
[33] B. Seon,et al. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. , 1986, Proceedings of the National Academy of Sciences of the United States of America.